Ligand Pharmaceuticals (LGND) Enterprise Value Growth (3y) (2013 - 2026)
Ligand Pharmaceuticals (LGND) Enterprise Value Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -40.23% |
| Dec 31, 2025 | -51.28% |
| Sep 30, 2025 | -76.23% |
| Jun 30, 2025 | -18.32% |
| Mar 31, 2025 | -0.79% |
| Dec 31, 2024 | 9.10% |
| Sep 30, 2024 | 38.62% |
| Jun 30, 2024 | 49.76% |
| Mar 31, 2024 | 2.89% |
| Dec 31, 2023 | 25.46% |
| Sep 30, 2023 | 37.89% |
| Jun 30, 2023 | 35.33% |
| Mar 31, 2023 | 27.40% |
| Dec 31, 2022 | 41.71% |
| Sep 30, 2022 | 52.03% |
| Jun 30, 2022 | 19.85% |
| Mar 31, 2022 | -18.10% |
| Dec 31, 2021 | -34.65% |
| Sep 30, 2021 | -34.02% |
| Jun 30, 2021 | 18.17% |